| 商品名称 | Mepact |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Osteosarcoma |
| 通用名/非专利名称 | mifamurtide |
| 活性成分 | mifamurtide |
| 产品号 | EMEA/H/C/000802 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | L03AX15 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2009/03/06 |
| 上市许可开发者/申请人/持有人 | Esteve Pharmaceuticals, S.A. |
| 人用药物治疗学分组 | Immunostimulants |
| 兽用药物治疗学分组 | |
| 欧盟委员会决定日期 | 2025/12/18 |
| 修订号 | 22 |
| 治疗适应症 | Mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with postoperative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2016/12/14 |
| 最后更新日期 | 2025/12/18 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/mepact-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/mepact |